The key facts about a meet are not explicitly mentioned in the provided evidence. However, based on the context, a meet can be understood as a gathering or an event where people come together to discuss, share, or participate in a particular activity.
In the context of the provided evidence, it appears that the term “meet” is used in relation to a meeting or gathering of the FDA with REGENXBIO. The key facts mentioned in the evidence are that the FDA is reconsidering REGENXBIO and that there is a July meeting and a Q3 BLA resubmission.
The evidence does not provide specific information about the nature of a meet in general. It only mentions the term in relation to the FDA’s meeting with REGENXBIO. Therefore, any general information about meets would not be supported by the provided evidence.